skip to Main Content

NRG1 Fusions in KRAS Wild-type Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
We used whole-genome and transcriptome sequencing to identify clinically actionable genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC).

Molecular characterization of 17 PDAC patients enrolled in a precision oncology program revealed gene fusions amenable to pharmacologic inhibition by small-molecule tyrosine kinase inhibitors in all patients with KRAS wild-type (KRASwt) tumors.  Read more . . . 

Back To Top